Page 1 of 1 MARKET RELEASE 3 August 2012 HealthLinx Limited TRADING HALT The securities of HealthLinx Limited (the “Company”) will be placed in Trading Halt Session State at the request of the Company, pending the release of an announcement by the Company. Unless ASX decides otherwise, the securities will remain in Trading Halt Session State until the earlier of the commencement of normal trading on Tuesday, 7 August 2012 or when the announcement is released to the market. Security Code: HTX Kobe Li Senior Adviser, Listings (Melbourne) HealthLinx Limited ABN 88 098 640 352 576 Swan Street Richmond VIC 3121 Telephone: +61 3 9208 4200 I Facsimile: +61 3 9208 4201 www.healthlinx.com.au 3 August 2012 ASX Market Announcements Australian Securities Exchange Limited Level 4, Rialto, 525 Collins Street, Melbourne VIC 3000 REQUEST FOR TRADING HALT In accordance with Listing Rule 17.2 the Company requests a trading halt pending a material price sensitive announcement. The reasons are: • The Company expects to make a material price sensitive announcement within the next 24 hours regarding a substantial asset sale; • The Company is concerned about confidentiality because outside parties have been involved in various ways; • The Company requests that trading be halted at market open today until immediately after the expected announcement is made or until 10:00am on Monday August 6, whichever is the earlier; • The Company is not aware of any reason why its securities should not be temporarily suspended. Mal Lucas-Smith Company Secretary About HealthLinx Limited (ASX:HTX) HealthLinx uses biomarkers to develop best practice diagnostics that detect and monitor diseases. First commercial targets are for diseases with high fatality: • Ovarian cancer diagnostic (OvPlex) targeting US$270m pa market • Prostate cancer targeting US$350m pa market A biomarker is a specific biochemical in the body that measures disease or the effects of treatment. HealthLinx is close to completing the second larger study for OvPlexTM aiming to prove the diagnostic accuracy for ovarian cancer. This larger study is based on approximately 1150 new samples using existing OvPlex™ biomarkers. The study will be a robust comparison of sensitivity and specificity especially for early stage diagnosis in symptomatic women. The objective is to cement the position of OvPlex™ as the world’s most accurate and efficient ovarian cancer diagnostic. The second study is partially funded with $750,000 from the Victorian Government Victoria’s Science Agenda Investment
HTX Price at posting:
0.2¢ Sentiment: Buy Disclosure: Held
